Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Jul 25 - Jul 30
PubMed Central PMCID: PMC3328245
and primary myelofibrosis
Mensink RP
5-a]pyrimidinescaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selectiveMLPCN probe
704869-38-5
Ambrisentan 1267 PubMed Central PMCID: PMC3328245Ambrisentan, also known as BSF 208075 and LU 208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6 minute walk distance) compared with placebo in two double blind, multicenter trials (ARIES 1 and ARIES 2). Ambrisentan was approved by
US$ 13.00
US$ 185.00
US$ 284.00
US$ 161.00
US$ 145.00